$PBYI

WILSON TROY EDWARD sold $46K of PBYI

WILSON TROY EDWARD sold 5,000 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.10 on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILSON TROY EDWARD
Published Sep 17, 2026, 1:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PBYI
Bearish
medium confidence
Mentioned
$PBYI
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PBYIBearishLow
01

Why it matters

The transaction is small relative to total holdings and likely has limited immediate market impact, but signals a slight negative sentiment.

02

Market read

Relevant for traders monitoring insider activity in biotech stocks; may influence short‑term trading decisions.

03

What to watch

Director still holds 54,750 shares, indicating continued confidence; broader market conditions may dominate price movement.

Relevance 2/10Novelty 4/10Timing: post‑market 2026-09-14 filing

Background

Form 4 filing discloses a director's sale of Puma Biotechnology shares under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$PBYIBearishMedium confidence
Context

Director Wilson Troy Edward sold 5,000 shares of Puma Biotechnology for $45,500 on 2026-09-14.

Expected impact

Potential short-term dip of 1‑2% if market reacts to insider sell.

Evidence & confidence

Sale amount is modest relative to total holdings; executed under pre‑arranged plan, reducing informational value.

Market effects

Minimal effect on biotech sector; insider sales are common and not sector‑wide catalyst.

No notable regional impact.

Limited to investors tracking Puma Biotechnology.

Counterpoint

Insider sale may be routine under 10b5‑1; price could remain stable or rise on fundamentals.

Key entities

  • Puma Biotechnology, Inc.

    Biotech firm developing oncology therapies.

  • Wilson Troy Edward

    Director of Puma Biotechnology.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PBYIMedAI 9/10

Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.

$PBYIMedAI 8/10

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.

$PBYIMed

PUMA BIOTECHNOLOGY, INC. (PBYI): Results of Operations and Financial Condition

PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,